Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey

By sjmartinez • January 17, 2024

Lu Y, Liu Y, Jastreboff AM, Khera R, Ndumele CD, Rodriguez F, Watson KE, Krumholz HM. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e010640. doi: 10.1161/CIRCOUTCOMES.123.010640. Epub 2023 Nov 11. Erratum in: Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e000126. PMID: 37950677; PMCID: PMC10782930.

Tags: adult, Cardiology/Epi, cardiovascular diseases, Ethnicity, Obesity, overweight, Publications

Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase in Aeromonas spp

von Bredow B, Trejo M, Ward KW, Trieu KP, Santellan CA, Garner OB, Yang S, Chandrasekaran S. Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase[...]

Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial

Budoff MJ, Verghese D, Kinninger A, Lakshmanan S. Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial. Eur Heart J Cardiovasc Imaging. 2026[...]

Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population

Spencer-Bonilla G, Fan J, Cheng P, Din N, Rodriguez F, Davies M, Papas MA, Huang J, Venditto J, Witteles RM, Heidenreich P, Alexander K, Sandhu[...]